CUE
Cue Biopharma
NASDAQ: CUE · HEALTHCARE · BIOTECHNOLOGY
$14.74
+13.38% today
Updated 2026-04-30
Market cap
$57.60M
P/E ratio
—
P/S ratio
2.10x
EPS (TTM)
$-8.40
Dividend yield
—
52W range
$5 – $31
Volume
11.4M
Cue Biopharma (CUE) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $7.31M | $16.28M | $66.95M | $45.36M | $71.61M | $99.53M | $83.40M | $91.28M | $61.53M | $32.19M |
| Cash & equivalents | $6.41M | $14.93M | $63.53M | $20.80M | $44.29M | $74.87M | $64.37M | $51.61M | $48.51M | $22.46M |
| Current assets | $6.51M | $15.14M | $65.07M | $40.61M | $61.02M | $87.53M | $68.47M | $77.19M | $51.45M | $25.14M |
| Total liabilities | $376295.00 | $1.10M | $5.35M | $11.39M | $17.02M | $20.62M | $17.91M | $25.60M | $24.45M | $14.69M |
| Current liabilities | $342205.00 | $1.07M | $5.35M | $6.22M | $11.66M | $16.32M | $12.79M | $11.55M | $17.08M | $13.69M |
| Long-term debt | — | — | — | — | — | — | — | $8.03M | $4.20M | — |
| Shareholder equity | $6.94M | $15.17M | $61.61M | $33.97M | $54.58M | $78.91M | $65.49M | $65.68M | $37.09M | $17.50M |
| Retained earnings | $-1.93M | $-9.59M | $-32.82M | $-71.80M | $-108.50M | $-153.29M | $-197.45M | $-250.46M | $-301.19M | $-341.86M |
| Accounts receivable | — | — | $852376.00 | — | $754898.00 | $1.42M | $3.14M | $57000.00 | $1.70M | $945000.00 |
| Inventory | — | — | $225500.00 | — | $15.12M | — | $1.00 | $1.00 | $1.00 | — |
| Goodwill | — | — | — | — | — | — | — | — | — | — |